Sandoz Unveils Strategy for 'Golden Decade' of Affordable Medicines

Sandoz Group AG, a leader in affordable medicines, plans to seize the unprecedented market potential of the next decade, with over USD 600 billion in medicines losing exclusivity. This opportunity to enhance patient access was outlined at the 44th Annual J.P. Morgan Healthcare Conference by CEO Richard Saynor.

Sandoz has established itself as a strong standalone player, making significant investments in biosimilar production, including a USD 1.1 billion site in Slovenia, and acquiring Just-Evotec Biologics' facility in France. It has launched six biosimilars in 2025 and increased capacity in its European antibiotic production network.

Looking ahead, Sandoz focuses on a USD 340 billion generic opportunity and a USD 322 billion biosimilar market, supported by a pipeline of over 400 assets. With this strategy, Sandoz aims to drive a 'golden decade' of affordable healthcare.